Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Core Insights - Cytek Biosciences, Inc. has been awarded "Overall BioTech Company of the Year" in the fourth annual BioTech Breakthrough Awards program, recognizing its significant contributions to the biotechnology sector [1] - The BioTech Breakthrough Awards program evaluates and acknowledges outstanding life sciences and biotechnology companies globally, with thousands of nominations from 14 countries this year [1] Company Overview - Cytek is recognized as a pioneer in spectral flow cytometry, known for its innovative approach that enhances the understanding of cell biology, immunology, oncology, and targeted therapeutic methodologies [2] - The company offers advanced cell analysis tools through its patented Full Spectrum Profiling™ (FSP™) technology, which includes core instruments like the Cytek Aurora™ and Northern Lights™ systems, as well as a range of other products and services [2][6] Industry Impact - Cytek's deep engagement with the cell analysis community has led to over 2,100 peer-reviewed articles published in prominent academic journals, showcasing the effectiveness of its products in addressing critical challenges [3] - The company aims to make flow cytometry more accessible, thereby facilitating a broader range of discoveries and equipping scientists with essential tools for research and innovation [4][5] Technology and Products - Cytek's FSP platform is designed to deliver high-resolution, high-content, and high-sensitivity cell analysis, utilizing the full spectrum of fluorescent signals for enhanced multiplexing capabilities [6] - The product lineup includes the Cytek Aurora™ CS system for cell sorting, flow cytometers, imaging products under the Amnis® and Guava® brands, and a digital ecosystem known as Cytek Cloud [2][6] Leadership Perspective - The CEO of Cytek, Wenbin Jiang, emphasized the transformative potential of data collection and interpretation in cell analysis, highlighting the company's commitment to making flow cytometry technology more accessible for impactful research outcomes [5]